Parkinson's Disease Psychosis Epidemiology

Key Highlights:

• As per DelveInsight’s estimations, the total diagnosed prevalent cases of PDP in the 7MM was approximately 911 thousand cases in 2023 and are projected to increase during the forecast period.
• DelveInsight’s analysis estimates that among the total diagnosed prevalent cases of PDP in 7MM approximately 53% of cases were from the US. As per our estimations, in 2023, the US accounted for nearly 484 thousand diagnosed prevalent cases of Parkinson’s disease Psychosis.
• According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately 1,211 thousand in the US in 2023 which is expected to increase during the forecast period (2024–2034) due to increasing awareness, aging population, and advancement of diagnostic procedures.
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of PDP, with 494 thousand cases, followed by France and the UK in 2023. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2023.

DelveInsight’s “Parkinson’s Disease Psychosis (PDP) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Parkinson’s Disease Psychosis (PDP), historical and forecasted epidemiology of Parkinson’s Disease Psychosis (PDP) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Parkinson’s Disease Psychosis (PDP) Understanding 

Parkinson’s Disease Psychosis (PDP) Overview

Psychosis is a serious mental health condition characterized by a loss of contact with reality, impacting thoughts and emotions. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases, Tenth Revision (ICD-10), psychosis appears in various disorders, including schizophrenia, bipolar disorder with psychotic features, and Parkinson’s disease.

In the DSM-5, psychotic disorders are defined more by clinical syndromes than by specific diseases and are differentiated primarily by their duration (for instance, symptoms of schizophrenia last at least six months, while brief psychotic disorder symptoms last less than a month), symptom types (schizophrenia presents multiple psychotic symptoms, while delusional disorder features only delusions), the relationship of psychotic symptoms to mood disturbances (whether they occur during or after mood episodes), and their underlying causes (including substance use or medical conditions like epilepsy, Systemic Lupus Erythematosus, tumors, or dementias). In clinical terms, "psychotic symptoms" refer to cognitive or perceptual dysfunctions such as delusions or hallucinations, while "psychotic disorder" indicates a condition where these symptoms fulfill specific diagnostic criteria.

Parkinson’s Disease Psychosis (PDP) Diagnosis

Despite various theories regarding its causes and underlying mechanisms, the diagnosis of psychotic disorders remains primarily clinical. It relies heavily on the patient's history, observed behaviors, subjective experiences, and findings from the mental status examination. Diagnostic tests, such as neuroimaging, electroencephalography (EEG), genetic testing, toxicology screenings, and serological evaluations, are generally reserved for select patients—typically those experiencing their first episode of psychosis or exhibiting symptoms linked to pre-existing neurodegenerative disorders, medical issues, or substance abuse. While some of these tests can highlight differences between psychotic individuals and those without mental disorders, none are reliably sensitive or specific enough to diagnose psychosis on an individual level. However, they do help uncover biological principles related to the pathophysiology of psychosis.

Further details related to diagnosis are provided in the report…

Parkinson’s Disease Psychosis (PDP) Epidemiology

For the purpose of designing the patient-based model for Parkinson’s Disease Psychosis (PDP), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Parkinson’s Disease and Total Diagnosed Prevalent Cases of Parkinson’s Disease Psychosis (PDP) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2021 to 2034. 

• The total diagnosed prevalent cases of Parkinson’s disease in the 7MM were 2,718 thousand in 2023 and are expected to increase at a significant CAGR of throughout the forecast period.
• In 2023, Japan contributed ~258 thousand diagnosed prevalent cases of Parkinson’s disease, representing almost 9% of the total diagnosed prevalence across the 7MM.
• Among the 7MM, EU4 and the UK accounted for nearly 353 thousand diagnosed prevalent cases of PDP, and these cases are expected to increase during the forecast period (2024–2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of PDP, with ~134 thousand cases, followed by France and Italy in 2023. On the other hand, the UK had the lowest diagnosed prevalent population in EU4 and the UK in 2023. 
• In Japan, there were around 74 thousand diagnosed prevalent cases of PDP in 2023. These cases are expected to increase at a significant CAGR.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Texas Health Science Center, San Antonio, US, Johns Hopkins University, Baltimore, US, Harvard Medical School, Boston, US, Georgetown University, Washington DC, US, University of Heidelberg, Germany, IU International University, Erfurt, Fondation Fondamental, Créteil, France, Università di Palermo, Palermo, Italy, King’s College, London, Tokyo University Hospital, Tokyo, Kyoto University Hospital, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of Parkinson’s Disease Psychosis (PDP) explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Parkinson’s Disease Psychosis (PDP) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of Parkinson’s Disease 
• Total Diagnosed Prevalent Cases of Parkinson’s Disease Psychosis (PDP)

Parkinson’s Disease Psychosis (PDP) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Parkinson’s Disease Psychosis (PDP) Epidemiology Segmentation 
• Parkinson’s Disease Psychosis (PDP) Report Assessment
• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Parkinson’s Disease Psychosis (PDP)? What will be the growth opportunities across the 7MM concerning the patient population of Parkinson’s Disease Psychosis (PDP)?
• What is the historical and forecasted Parkinson’s Disease Psychosis (PDP) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the prevalent cases of Parkinson’s Disease Psychosis (PDP) in Japan lower than the US?
• Which country has a high patient share for Parkinson’s Disease Psychosis (PDP)?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Parkinson’s Disease Psychosis (PDP) prevalent cases in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Parkinson’s Disease Psychosis (PDP) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Parkinson’s Disease Psychosis (PDP) cases in 2023?

The highest cases of Parkinson’s Disease Psychosis (PDP) was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Parkinson’s Disease Psychosis (PDP) cases in 2023?

The highest cases of Parkinson’s Disease Psychosis (PDP) were found in the US among the 7MM in 2023.